WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced that the American Society of Clinical Oncology (ASCO) has accepted for oral presentation the Company’s abstract for ARQ 197 (A Phase 1 Dose Escalation Study of ARQ 197, a Selective Inhibitor of the c-Met Receptor in Patients with Metastatic Solid Tumors) at the 43rd ASCO Annual Meeting, June 1-5, 2007, in Chicago. This presentation will describe findings from a Phase 1 trial with ARQ 197, a selective, small molecule inhibitor of the c-Met receptor tyrosine kinase, in cancer patients with a broad range of metastatic solid tumor types who had failed prior treatment regimens.
